Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$569.90 USD

569.90
993,348

-1.64 (-0.29%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $570.26 +0.36 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Zacks Equity Research

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Zacks Equity Research

Here's Why You Should Add Alnylam (ALNY) Stock to Your Portfolio

by Zacks Equity Research

Alnylam's (ALNY) revenues continue to be driven by Amvuttra and Givlaari sales. Its existing collaboration agreement with Regeneron to develop RNAi-based candidates is progressing well.

Zacks Equity Research

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Zacks Equity Research

What's in Store for Thermo Fisher (TMO) in Q2 Earnings?

by Zacks Equity Research

Thermo Fisher (TMO) is likely to have generated growth in the second quarter, driven by a favorable business mix and new launches.

Zacks Equity Research

Alnylam (ALNY) Posts Upbeat Data From Alzheimer's Disease Study

by Zacks Equity Research

Alnylam (ALNY) announces positive interim analysis data from the Part A of its early-stage study of ALN-APP in the treatment of early-onset Alzheimer's disease and cerebral amyloid angiopathy.

Zacks Equity Research

Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

UnitedHealth Group (UNH) Q2 Earnings Beat, Boosts '23 EPS View

by Zacks Equity Research

UnitedHealth Group's (UNH) Q2 results benefited on the back of solid contributions from the UnitedHealthcare and Optum segments. Management presently forecasts adjusted net EPS within $24.70-$25.00 for 2023.

Zacks Equity Research

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks Equity Research

Regeneron (REGN) Loses 13% in Three Months: What Lies Ahead?

by Zacks Equity Research

Regeneron (REGN) declines 13% in the last three months due to regulatory setback for 8 mg dose strength of aflibercept and competition for lead drug.

Zacks Equity Research

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Zacks Equity Research

Catalent's (CTLT) Facility Snag Linked to Regeneron's Eylea CRL

by Zacks Equity Research

Catalent's (CTLT) drug manufacturing facility in Indiana faces problems, which is linked to FDA's rejection of Regeneron's eye drug application. This is the latest in a string of quality control issues for Catalent.

Zacks Equity Research

The Zacks Analyst Blog Highlights Texas Instruments, Regeneron Pharmaceuticals, Micron Technology, FedEx and Arista Networks

by Zacks Equity Research

Texas Instruments, Regeneron Pharmaceuticals, Micron Technology, FedEx and Arista Networks are included in this Analyst Blog.

Zacks Equity Research

Sanofi (SNY) Atopic Dermatitis Drug Meets Goals in Phase II Study

by Zacks Equity Research

Sanofi's (SNY) phase II study, investigating amlitelimab for moderate-to-severe atopic dermatitis in adults, meets the primary endpoint.

Mark Vickery headshot

Top Analyst Reports for Texas Instruments, Regeneron & Micron Technology

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Inc. (TXN), Regeneron Pharmaceuticals, Inc. (REGN) and Micron Technology, Inc. (MU).

Zacks Equity Research

Regeneron (REGN) Gets CRL for Aflibercept 8 mg Drug, Shares Fall

by Zacks Equity Research

Regeneron (REGN) receives a completed response letter for the application seeking approval of aflibercept 8 mg for treating several retinopathic indications. The stock falls 9% following the news.

Zacks Equity Research

Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed at $771.11 in the latest trading session, marking a +0.49% move from the prior day.

Zacks Equity Research

Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Regeneron (REGN) closed at $750.12, marking a +1.56% move from the previous day.

Zacks Equity Research

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE

Zacks Equity Research

Is First Trust NASDAQ-100 Equal Weighted ETF (QQEW) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for QQEW

Zacks Equity Research

Kodiak (KOD) Advances With Tarcocimab Amid Stiff Competition

by Zacks Equity Research

Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of other candidates in the pipeline are concerns.

Zacks Equity Research

Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study

by Zacks Equity Research

A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.

Zacks Equity Research

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Zacks Equity Research

Alimera (ALIM) Completes Enrollment in Eye Disease Study

by Zacks Equity Research

Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular edema. The stock surges 8% on Wednesday.

Zacks Equity Research

The Zacks Analyst Blog Highlights AbbVie, Intel, Qualcomm, Regeneron and CME Group

by Zacks Equity Research

AbbVie, Intel, Qualcomm, Regeneron and CME Group are included in this Analyst Blog.